血清chemerin 水平与代谢综合征患者合并冠心病的相关性研究

目的:旨在探讨血清脂肪因子chemerin水平与代谢综合征患者合并冠心病的相关性。方法:共纳入116名代谢综合征患者,将所有患者分为两组,合并冠心病组(CAD+,n=47)及未合并冠心病组(CAD-,n=69),使用酶联免疫吸附(ELISA)法测量每组血清的血清chemerin水平。结果:CAD+组患者的血清chemerin水平较CAD-组患者显著升高(129.83±29.18 vs 94.01±23.54 ng/mL;P<0.01),多元Logistic回归分析结果显示血清chemerin水平与代谢综合征患者合并冠心病存在独立相关性(优势比1.565,95%可信区间1.104-2.876;P<0.05)。结论:血清chemerin水平是代谢综合征患者合并冠心病的独立危险因子,血清chemerin可能是预测代谢综合征患者发生冠心病风险的重要的生物学标记物。

The Association of Serum Chemerin Levels with the Presence of Coronary Artery Disease in Patients with Metabolic Syndrome

Objectives: The aim of this study is to investigate the correlation of serum chemerin levels with coronary artery disease(CAD) in patients with metabolic syndrome(MetS).Methods: 116 patients with MetS were included in this study.All the patients were classified as patients with CAD(CAD+,n=47) or as without CAD(CAD-,n=69).Serum chemerin levels were measured by enzyme-linked immunosorbent assay(ELISA).Results: Serum chemerin levels were significantly higher in MetS patients with CAD compared with those without CAD(129.83±29.18 vs 94.01±23.54 ng/mL;P<0.01).Multivariate logistic regression revealed that serum chemerin levels were independently associated with the presence of CAD in patients with MetS(odds ratio 1.565,95% confidence interval 1.104-2.876;P<0.05).Conclusion: Serum chemerin levels were an independent determinant of the presence of CAD in MetS patients.These results demonstrated that chemerin might be a potentially useful biomarker for predicting the presence of CAD in MetS patients.